Compugen Ltd
NASDAQ:CGEN
Compugen Ltd
NASDAQ:CGEN
Price:
1.91 USD
-3.54%
Market Closed
Updated:
Apr 25, 2024
Section:
Relative Value
The Relative Value of one
CGEN
stock under the Base Case scenario is
1.74
USD.
Compared to the current market price of 1.91 USD,
Compugen Ltd
is
Overvalued by 9%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CGEN
Relative Value
Base Case
1.74
USD
Overvaluation 9%
Valuation Multiples
Multiples Across Competitors
CGEN Competitors Multiples
Compugen Ltd Competitors
Compugen Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IL |
|
Compugen Ltd
NASDAQ:CGEN
|
170.4m USD | 5.1 | -9.1 | -9.6 | -9.2 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
221.5B USD | 5.2 | 37 | 22.8 | 33.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
182.6B USD | 7.6 | 38.5 | 26 | 36.7 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
42.3B USD | 2.8 | 31.2 | 16.9 | 26.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
37.1B CHF | 5.5 | 56.7 | 19.5 | 28.5 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.5T KRW | 15 | 64.7 | 34.1 | 49.1 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
39.9B USD | 5.9 | 32.3 | 25.8 | 31 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
27.4B USD | 9.3 | 46.2 | 31.6 | 37.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.2B USD | 6.9 | 33.3 | 23.3 | 25.9 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
24.8B USD | 3.1 | 40.5 | 17.2 | 26.9 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.7B EUR | 6.9 | 73.6 | 31.8 | 52.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
